OncoHost

About:

OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.

Website: http://oncohost.com

Twitter/X: OncoHost

Top Investors: OurCrowd, BIRD Foundation, Leumi Partners, Menora Mivtachim, ALIVE Israel HealthTech Fund

Description:

OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners. OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance. OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.

Total Funding Amount:

$52.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Binyamina, Hefa, Israel

Founded Date:

2017-01-01

Contact Email:

Ofer(AT)OncoHost.com

Founders:

Dr. Dror Yeger, Yuval Shaked

Number of Employees:

11-50

Last Funding Date:

2022-05-10

IPO Status:

Private

Industries:

© 2025 bioDAO.ai